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Abstract
Translocation events are frequent in cancer and may create chimeric fusions or ‘regulatory 
rearrangements’ that drive oncogene overexpression. Here we identify super-enhancer 
translocations that drive overexpression of the oncogenic transcription factor MYB as a recurrent 
theme in adenoid cystic carcinoma (ACC). Whole-genome sequencing data and chromatin maps 
reveal distinct chromosomal rearrangements that juxtapose super-enhancers to the MYB locus. 
Chromosome conformation capture confirms that the translocated enhancers interact with the 
MYB promoter. Remarkably, MYB protein binds to the translocated enhancers, creating a positive 
feedback loop that sustains its expression. MYB also binds enhancers that drive different 
regulatory programs in alternate cell lineages in ACC, cooperating with TP63 in myoepithelial 
cells and a Notch program in luminal epithelial cells. Bromodomain inhibitors slow tumor growth 
in ACC primagraft models in vivo. Thus, our study identifies super-enhancer translocations that 
drive MYB expression and provides insight into downstream MYB functions in the alternate ACC 
lineages.
Introduction
Chromosomal rearrangements that create a chimeric fusion gene or drive oncogene 
overexpression are common in cancer. The discovery of the “Philadelphia chromosome” 
translocation in chronic myelogenous leukemia, which creates the BCR-ABL fusion gene, 
ushered in an era of targeted therapy with kinase inhibitors. Oncogenic rearrangements that 
juxtapose a strong enhancer near an oncogene, triggering its overexpression, are also 
frequent in leukemia and lymphoma1–3. Recently, a similar enhancer hijacking mechanism 
was described in medulloblastoma4, wherein chromosomal translocations involving 
enhancers cause over-expression of GFI1 or GFI1B, which function as transcriptional 
repressors of tumor suppressor genes. In other cases, translocation events drive the 
expression of an oncogene by replacing its promoter with a highly active promoter, as is the 
case for TMPRSS2-ERG fusions in prostate cancer5.
Adenoid cystic carcinoma (ACC) is a malignant neoplasm that arises within the secretory 
glands, most commonly in the salivary glands of the head and neck. Though typically slow 
growing, these tumors are locally aggressive, with a tendency to spread along nerves. 
Perhaps most challenging clinically, ACC can recur loco-regionally or with distant 
metastases decades after primary tumor resection, requiring careful long-term surveillance 
of all patients. Due to the resistance of these tumors to chemotherapy and radiation therapy, 
non-resectable cases are usually fatal6.
The MYB-NFIB translocation is a molecular hallmark that is present in a majority of ACC7. 
MYB is a master transcription factor (TF) involved in cellular differentiation and 
proliferation. It functions as an oncogene in a variety of cancers, including breast cancer, 
pancreatic cancer, and leukemia8. The MYB-NFIB translocation reportedly disrupts the 
MYB 3′UTR, which contains a microRNA (miRNA) regulatory site that down-regulates 
MYB expression9. However, MYB translocations that retain the 3′UTR are still associated 
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with high MYB expression, indicating the existence of additional mechanisms for MYB 
overexpression in ACC.
Here we identify the juxtaposition of super-enhancer regions to the MYB locus as the 
unifying feature of ACC translocations. Detailed genomic and epigenomic analyses of ACCs 
reveal alternate rearrangements that translocate super-enhancers in the NFIB and TGFBR3 
loci either upstream or downstream of the MYB gene. MYB protein binds these super-
enhancers, which loop to the MYB promoter, thereby establishing a positive feedback loop 
that sustains expression of this master regulator. MYB also binds a larger repertoire of 
enhancers genome-wide, which appear to support alternate ACC expression signatures in the 
myoepithelial and luminal epithelial compartments of ACC. BET bromodomain inhibitors, 
which disrupt enhancer functions, slow tumor growth in ACC primagraft models in vivo. 
However, these inhibitors appear to be ineffective against high grade ACCs that harbor 
activating mutations in the Notch pathway. Thus, we identify a novel mechanism of 
transformation in which a regulatory element rearrangement creates a positive feedback loop 
between an oncogenic TF protein and its gene locus, with implications for diagnosis and 
therapeutic strategies in ACC.
Results
Novel MYB translocations in ACC
A diagnostic feature of ACC is a t(6:9) rearrangement that translocates MYB to the NFIB 
locus, and results in high MYB expression9. This translocation results in a fusion gene 
whose coding sequence is almost identical to MYB, but with an altered 3′UTR that lacks 
negative regulatory elements and leads to increased transcript stability9. Yet, while nearly all 
ACCs overexpress MYB, only about 30% carry an actual fusion transcript10.
We therefore examined whole genome sequencing data for 18 ACCs, including 12 published 
primary ACCs7,11 and 6 primary patient-derived xenografts (ACC primagrafts). Consistent 
with previous reports, we identified MYB translocations as the main recurrent event (13 out 
of 18 ACCs) in these tumors (Fig. 1a). We confirmed the presence of MYB rearrangements 
in four of these primagrafts by PCR. MYB rearrangements in the primagrafts were verified 
by FISH previously12. We also confirmed by PCR representative rearrangements involving 
other loci that were detected in the sequencing data (Supplementary Fig. 1, Supplementary 
Table 1). These results support the validity of rearrangements detected from whole genome 
sequencing data for these 18 ACCs. Finally, we identified MYB rearrangements in two 
additional tumors by targeted paired-end sequencing. This yielded a total of 15 (out of 20) 
ACCs with MYB rearrangements.
We identified canonical NFIB-MYB fusions with loss of the MYB 3′ UTR in 6 of the 20 
tumors (30%; Fig. 1b, Table 1). An additional 6 tumors (30%) harbor an NFIB-MYB 
rearrangement but retain the MYB 3′UTR. We also identified novel translocations involving 
the MYB locus: two tumors harbored rearrangements between MYB and the TGFBR3 
locus, and one tumor harbored a rearrangement between MYB and the RAD51B locus. We 
used quantitative RT-PCR to confirm that all of these rearrangements are associated with 
high levels of MYB expression (Fig. 1c). Notably, several rearrangements occur at the 5′ end 
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of the MYB gene, which is inconsistent with production of any fusion protein (Fig. 2a). 
These findings indicate that neither fusion gene products nor 3′ UTR loss are unifying 
features of ACC rearrangements, and raise the alternate possibility that these translocations 
increase MYB expression through regulatory alterations.
Enhancer rearrangements act as drivers of MYB activation
We postulated that ACC translocations might reposition distal regulatory elements in 
proximity to MYB, thereby triggering its overexpression. We therefore mapped the 
chromatin landscapes of 13 ACCs, including 5 primary specimens and 8 primagrafts. We 
mapped histone H3 lysine 4 trimethylation (H3K4me3), a promoter-associated mark, and H3 
lysine 27 acetylation (H3K27ac), a marker of active enhancers13. In a subset of samples, we 
also mapped the enhancer-associated BET bromodomain protein BRD4. Overall H3K27ac 
patterns were similar across primary ACCs and primagraft models, but distinct from an ACC 
cell line derived by viral transformation14. The ACC landscapes were distinct from other 
tumor types and non-malignant tissues (Supplementary Fig. 2). The conserved epigenomic 
landscapes between primary tumor and primagraft, together with the conserved histology12, 
support the fidelity of the in vivo primagraft models.
We next examined the genomic loci that were translocated to MYB in the various tumors – 
specifically, the regions downstream of NFIB, TGFBR3 and RAD51B. We found that all 
three regions contain large clusters of enhancers that are active in ACCs (Fig. 2c,e). Indeed, 
when we collated super-enhancers in ACCs based on expanse and signal intensity of 
H3K27ac15 and BRD4 occupancy16 we identified several super-enhancers in the rearranged 
portions of NFIB and TGFRB3 (Fig. 2b,c,e; Supplementary Fig. 3). We also identified 
smaller enhancers downstream of RAD51B, which was rearranged in one ACC 
(Supplementary Fig. 4). Interestingly NFIB, TGFBR3 and RAD51B are all highly expressed 
in normal salivary gland, suggesting these regions are indeed active before transformation 
(Supplementary Fig. 5). These findings suggest that the various rearrangements in ACC may 
act by repositioning potent regulatory elements close to MYB.
To test whether specific enhancers within the translocated super-enhancers might activate the 
MYB promoter, we examined their physical proximity using Chromosome Conformation 
Capture (3C). First, we examined an ACC with a translocation involving MYB and the 
NFIB locus. We examined 8 acetylated elements located between 13 and 750kb from the 
MYB promoter. We identified 4 elements that demonstrated a significant interaction with the 
MYB promoter (Fig. 2d). We also examined a second ACC with a MYB-TGFBR3 
translocation. In this case, 7 out of 9 tested H3K27ac peaks interacted with the MYB 
promoter (Fig. 2f). These data suggest that the translocations reposition super-enhancers that 
subsequently loop to the promoter and sustain high-level MYB expression.
Positive feedback MYB circuit
To examine potential downstream targets of MYB overexpression, we mapped MYB protein 
binding genome-wide in 3 ACC primagrafts using ChIP-Seq. MYB binding profiles were 
similar across the 3 ACC primagrafts and strongly enriched for the MYB motif in all 
samples (CAGTT, p<10−759). MYB binding patterns differ from published datasets for other 
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human and mouse tissues17,18, yet share a statistically significant overlap: 62% overlap with 
MYB-bound promoters in MCF7 (p<10−6); 60% overlap with MYB targets in mouse 
myeloid progenitors (p<10−51).
Notably, MYB binds to the enhancers in the NFIB and TGFBR3 loci that are translocated to 
the MYB locus in ACC (Fig. 3a). When we ranked MYB bound enhancers per gene by 
binding signal, the translocated enhancers were near the top ranked genes (NFIB, #5 in 
ACCX5M1, and #17 in ACCX16; TGFBR3, #77 in ACCX2; see Methods, Fig. 3b). 
Moreover, in the respective rearranged tumors, these MYB-bound enhancers physically 
interact with the MYB gene promoter (Fig. 2d,f; Fig. 3a). Thus, MYB binding to 
translocated enhancer clusters may augment its own expression by activating transcription of 
the MYB gene (Fig. 3c). To test whether the translocated enhancers can drive transcription 
in a MYB-dependent manner, we cloned five 250 bp intervals from the NFIB and TGFBR3 
enhancers into a minimal promoter vector. We tested these reporter constructs in Jurkat cells, 
which express high levels of MYB protein at baseline19. We found that four of the five 
elements strongly induce reporter activity. Moreover, we found that the activity of two of 
these elements was diminished when we mutated their MYB motifs (Supplementary Fig. 6). 
These data support the enhancer identify and MYB responsiveness of sequence elements 
juxtaposed to the MYB locus by rearrangements. They are most consistent with a model in 
which positive feedback sustains MYB expression in this disease.
MYB-related regulatory programs in ACC
To infer potential downstream effects of MYB overexpression, we called 13,278 high 
confidence MYB binding sites (Methods, Supplementary Table 2). A majority of these sites 
coincides with distal regulatory elements (75%), while a minority coincides with promoters 
(Fig. 3d). MYB shows a strong preference for active elements as marked by H3K4me3 
(promoters) or H3K27ac (enhancers). We predicted MYB target genes by assigning MYB-
bound enhancers to nearby genes that are expressed in ACC12 (Methods). These genes are 
expressed at relatively higher levels in the primagrafts, compared to all expressed genes, but 
are weakly expressed in normal salivary gland (Fig. 3e). We refer to these genes as putative 
MYB targets as they are probabilistic predictions based on binding profiles and expression 
patterns, whose further validation will require the development of faithful in vitro models for 
ACC.
Putative MYB targets in ACC are enriched for genes related to development, migration, cell 
signaling, cell cycle, transcription regulation and angiogenesis (REACTOME, Gene 
Ontology, MSigDB; FDR<1%, Supplementary Table 3). Specific examples include MYC, 
BCL2, AURKA, CCND1, MET, FGFR2, IGF1R, MALAT1, CASC4 and NENF. We 
compared these expression patterns to normal salivary gland20. Out of 4853 highly 
expressed MYB bound genes in ACC, 50% are also highly expressed in normal salivary 
gland, 38% show low levels of expression and 12% are not expressed. Functional annotation 
of putative MYB targets that are also expressed in the normal counterpart revealed 
enrichment for genes involved in neurodevelopmental processes. In contrast, putative MYB 
targets that are uniquely expressed in ACC are enriched for cell cycle regulators, including 
CDK6 and GMNN (Supplementary Table 2). Thus, MYB may engage two distinct 
Drier et al. Page 5
Nat Genet. Author manuscript; available in PMC 2016 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
regulatory circuits in ACC, one that reinforces a pre-existing neurodevelopmental program 
in salivary epithelial cells and another that drives proliferation.
We next sought to identify other TFs or pathways that mediate or cooperate with MYB-
driven regulatory programs in ACC. We scanned the high confidence MYB peaks collated 
above for enriched TF motifs. As expected, the top ranked motif corresponded to the MYB 
consensus. The second ranked motif is the TP53/TP63/TP73 consensus (p<10−340). TP63 
was also identified as a putative MYB target (Supplementary Fig. 7). To directly test 
whether TP63 co-binds with MYB, we mapped binding of this TF by ChIP-seq. 
Remarkably, we found that 81% of TP63 binding sites in ACC are co-bound by MYB 
(Supplementary Fig. 8). We next collated putative target genes near the top ranked MYB 
binding sites, focusing on TFs and transcriptional regulators (Fig. 3f, Supplementary Table 
4). This revealed activators such as EN1, recently identified as a biomarker for high grade 
ACC21, the ARID1A chromatin remodeler, which is mutated in ACC11, and NOTCH1. In 
addition to NOTCH1, the Notch activators, JAG1 and JAG2, and the Notch transcriptional 
repressor SPEN, were identified among these highly ranked putative MYB targets. These 
data suggest that MYB, TP63 and NOTCH signaling may coordinately orchestrate the 
diverse expression programs in ACC.
Inter- and intra-tumoral epigenetic heterogeneity in ACC
ACC is notable for its biphenotypic differentiation with myoepithelial and (luminal) 
epithelial cells arranged in a ‘cribriform’ pattern. This histology is seen in low grade (grade 
1 and 2) tumors, which constitute the majority of ACC cases. However, a smaller fraction of 
tumors have a ‘solid’ histology dominated by luminal epithelial cells, and are more 
aggressive (grade 3). Grade 3 tumors can originate from grade 2 tumors, but more 
commonly presented independently22,23. We therefore considered how MYB might promote 
these alternate cell fates in ACC.
We focused in particular on regulatory programs related to TP63 and Notch, which were 
both highlighted by our epigenomic analysis. We first examined the expression of these 
regulators in 19 grade 2 ACCs (Fig. 4a, Supplementary Fig. 9, Table 2). 
Immunohistochemistry (IHC) confirmed strong staining for TP63 – a marker of 
myoepithelial cells24 – specifically in the myoepithelial compartments. TP63 was 
conspicuously absent from the luminal epithelial tumor cells, which stain positive for KIT. 
We also stained these tumors for ICN1, the active intracellular form of NOTCH1. ICN1 is 
expressed only in the luminal epithelial cells, and is exclusive with TP63 (Fig. 4b). This 
exclusivity is consistent with established antagonism between TP63 and NOTCH1 during 
development25,26. Thus, MYB appears to coordinate seemingly opposing regulatory 
programs in the distinct cellular compartments of ACC.
We next examined TP63 and NOTCH1 expression in eight grade 3 ACCs. These more 
aggressive specimens lack TP63 staining, consistent with loss of the myoepithelial 
component. Remarkably, they all show strong diffuse staining for ICN1. ACCs can harbor 
activating mutations in NOTCH1 or loss of function mutations in the RBPJ repressor 
SPEN7,11,27. These mutations are present in 7 out of 9 grade 3 tumors, but none of the lower 
grade tumors examined (Supplementary Table 5). The other two grade 3 tumors display 
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NOTCH1 alterations that may also upregulate Notch signaling- ACC X11 has a tandem 
duplication 3′ of NOTCH1, in a region containing NOTCH1 enhancers; ACC D1 has partial 
5′ deletion of NOTCH1, similar to deletions we and others recently detected in breast cancer 
and T-ALL27–29.
To gain further insight into the circuits that drive these respective regulatory programs, we 
compared enhancer patterning between low and high grade ACCs. First, we performed 
unsupervised clustering of putative active enhancers based on their H3K27ac patterns across 
13 primagrafts and primary tumors (Supplementary Fig. 10). This analysis distinguished sets 
of enhancers preferential to either grade 2 or grade 3 tumors, which we then scanned for 
over-represented TF motifs (Fig. 3g). The TP63 motif was highly enriched in grade 2 
specific enhancers, while the RBPJ/Notch motif was enriched in grade 3 specific enhancers. 
TP63 exists in two main isoforms, TAp63, a transcriptional activator, and ΔNp63, which 
lacks the transactivation domain and exerts stem-like and oncogenic functions30. Only the 
oncogenic isoform ΔNp63 is transcribed in our ACC cohort (Supplementary Fig. 7), as is 
frequently the case in salivary tumors31.
Thus, TP63 appears to be a mediator of the MYB regulatory program in the myoepithelial 
component of low grade ACCs. Conversely, Notch signaling is active in luminal epithelial 
components of low grade ACC. Its further activation by somatic Notch pathway gain-of-
function mutations likely underlies the switch to solid histology and the aggressive clinical 
course of grade 3 tumors.
BET and Notch inhibitors target alternate ACC phenotypes
Our findings suggest that chromosomal rearrangements in ACC engage a positive feedback 
loop, in which MYB protein activates juxtaposed super-enhancers, which loop to the MYB 
gene and sustain its expression. BET bromodomain inhibitors have been shown to suppress 
MYB function in acute myeloid leukemia32 and, more generally, may suppress super-
enhancers with strong BRD4 occupancy16. This suggests that MYB target loci in ACC, 
which also have high BRD4 occupancy (Supplementary Fig. 11), may be sensitive to BET 
bromodomain inhibition. We specifically hypothesized that grade 2 tumors would be 
particularly sensitive to bromodomain inhibitors given their prominent MYB regulatory 
circuits. In contrast, somatic Notch activation might render grade 3 tumors relatively less 
sensitive to bromodomain inhibition, as recently observed in T-ALL with activating 
NOTCH1 mutations33. We therefore examined the in vivo efficacy of BET inhibitors34 in 
ACC primagrafts. To this end, we engrafted nude mice with 4 different ACCs, two grade 2 
and two grade 3 tumors. We confirmed that both grade 3 primagrafts harbor genetic events 
leading to Notch activation (Supplementary Table 5), and stain strongly positive for ICN1 
and the proliferation marker Ki-67 (Fig. 4a). Randomized groups of 5 mice each were 
treated with vehicle or the BET bromodomain inhibitor JQ1, and tumor growth was 
measured over time (Fig. 5a). BET inhibition significantly slowed tumor growth in the grade 
2 primagrafts (Fig. 5b). We also detected a modest decrease in MYB and MYB target gene 
expression (Fig. 5c). In contrast, the grade 3 tumors did not respond to BET inhibition, 
potentially reflecting a relatively stronger dependency on Notch signaling. Of note, we 
recently showed that Notch-mutant ACCs are sensitive to Notch inhibitors27. Our results 
Drier et al. Page 7
Nat Genet. Author manuscript; available in PMC 2016 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
suggest that BET inhibitors may be sufficient to disrupt core MYB circuitry in low grade 
ACC, but are ineffective against high grade tumors, which may instead be sensitive to Notch 
inhibitors.
Discussion
Adenoid cystic carcinoma is an incurable disease with slow but chronic tumor progression 
that is refractory to conventional chemotherapy or radiation. We have shown that most cases 
of ACC harbor translocations that juxtapose a super-enhancer to the MYB locus. A 
convergence of genetic, epigenetic and therapeutic data indicate that these rearrangements 
establish a positive feedback loop in which MYB protein binds the translocated enhancers, 
which in turn physically interact with the MYB promoter and drive its expression. Thus, 
although MYB is known to autoregulate itself in wildtype cells35,36, enhancer hijacking 
events perturb this physiologic control in ACC, yielding a high degree of over-expression.
MYB coordinates with distinct regulatory programs in the alternate cell lineages in the 
cribriform grade 2 tumors, cooperating with a TP63 program in myoepithelial cells or a 
Notch program in luminal epithelial cells. In grade 3 tumors, however, additional genomic 
events frequently lead to constitutive Notch activation, and tip the balance towards the 
luminal epithelial fate, and a ‘solid’ histology. Grade 2 tumors appear dependent on 
bromodomain proteins to maintain MYB driven enhancer programs, as indicated by their 
sensitivity to the corresponding inhibitors. In contrast, grade 3 tumors with constitutive 
Notch activation are insensitive to bromodomain inhibitors, consistent with other Notch-
driven tumors. In grade 2 tumors, IHC staining for MYB tends to be stronger in 
myoepithelial cells than in luminal cells, in line with previous reports37,38, while grade 3 
tumors exhibit diffuse MYB staining with variable intensity across tumors (Supplementary 
Fig. 9). Although these differences may in part reflect technical issues, they raise the 
possibility that lower MYB protein levels in grade 3 tumors influence tumor response to 
BET inhibitors. In conclusion, our study advances understanding of ACC biology, and 
underscores how interplay between genetic and epigenetic alterations can affect malignant 
transformation, disease progression, and therapeutic sensitivities.
Online Methods
Primary tumors
Primary adenoid cystic carcinomas were collected at MD Anderson Cancer Center, 
University of Virgina, and Massachusetts General Hospital with approval by the respective 
Institutional Review Boards.
Primagraft experiments
To generate adenoid cystic carcinoma primagrafts, viable adenoid cystic carcinoma cells 
were injected into the flank of nude (Foxn1nu) mice. Tumors that grew were passaged 
through at least three rounds of nude transplantation prior to in vivo drug testing use. Studies 
were performed under the auspices of protocols approved by the University of Virginia 
IACUC12.
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For in vivo drug testing, 106 viable adenoid cystic carcinoma cells were injected into the 
flank of nude mice. Once tumor was visible, the mice were randomized to receive vehicle or 
JQ1 (50mg/kg daily) diluted in 10:90 DMSO:10%hydroxypropyl-beta-cyclodextrin orally 
until reaching minimal tumor volume of 1000 mm3 (4 – 9 mice per group: X5M1 & X6 4 
treated vs. 9 vehicle controls, X9 4 treated vs. 5 vehicle controls, X11 5 treated vs. 8 vehicle 
controls). Tumor growth was monitored and mice were weighed daily and sacrificed when 
moribund. In these experiments, no statistical methods were employed to determine the 
sample size, and no blinding of investigators was performed. All animal procedures used in 
this study were approved by the IACUC at START, Texas.
Cell lines
The HPV-transformed ACC cell line ACC112 was cultured in RPMI supplemented with 
10% fetal bovine serum, Epidermal Growth Factor, Hydrocortisone and Insulin (all from 
R&D) as previously described 14. Jurkat cells were obtained from ATCC and Oci-Ly3 cells 
from the Broad-Novartis Cancer Cell Line Encyclopedia. Both cell lines were cultured in 
RPMI with 10% fetal bovine serum and propagated at a density of 1 – 2 million cells per 
mL.
Calling MYB translocations
MYB translocations were called from paired-end whole genome sequencing data using the 
following datasets. Data of 12 primary tumors were obtained from the European Genome-
phenome Archive, study EGAS00001000030. Out of the 12 tumors, 5 tumors were not 
considered for analysis due to low coverage or unreliable paired-end alignment. Data of 5 
additional tumors were recently published and included in the analysis7. We performed 
100bp paired end whole genome sequencing for 6 additional patient derived primagrafts 
with Illumina HiSeq. MYB translocation in the ACC primagrafts X5M1 and X11 were 
detected by paired end sequencing of H3K27ac ChIP-Seq and input control. All fastq files 
were aligned to the reference genome (hg19) using BWA ALN. Reads from primgrafts that 
align to the mouse genome (mm10) with maximal editing distance of 3bp (based on BWA 
alignment) were filtered out. Rearrangements were called with dRanger and 
BreakPointer39,40. Due to the lack of matching normal controls, we could not use the default 
germline filtering. Instead we have filtered against a panel of 100 non-matched normals, 
defining the rearrangement score as 10*q*t/max(n,1), where q is the quality (as defined by 
dRanger), t the number of supporting read pairs in the tumor, and n the average number of 
supporting reads in the normals. Only rearrangement with score >= 5 were kept. Known 
germline variants from the DGV database41 were filtered out. Intra-chromosomal 
rearrangements that span less than 1Mb were filtered out, as they were suspected to be 
germline. Rearrangements from ChIP-seq paired end data were called as previously 
described42. All MYB translocations were manually reviewed in IGV43. Only MYB and 
NFIB were found to have recurrent rearrangements in more than two primagrafts (even 
when considering all rearrangements with score >= 3). CDH18, EYS and TAF13 were 
rearranged in two primagrafts, but not in the other 12 primary tumors. All new data has been 
deposited at the European Genome-phenome Archive (EGA), which is hosted by the EBI, 
under accession number EGAS00001001457.
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Chromatin immunoprecipitation
We performed chromatin immunoprecipitation (ChIP) in primary tumors and primagrafts as 
described with the following modifications44. Frozen tissue was chopped up using a scalpel 
before fixation and then further dissociated after fixation by shearing with an 18G needle. 
Chromatin from formaldehyde-fixed cells (1–5 × 106 cells per histone mark, 107 cells for 
MYB binding) was fragmented to a size range of 200–700 bases with a Branson 250 
Sonifier. Solubilized chromatin was immunoprecipitated with antibody against H3K4me3 
(2.5 μl; Millipore, 07-473CA), H3K27ac (2.5 μl; Abcam, ab4729), MYB (10 μl; Bethyl, 
A304-136A) and TP63 (5 μl; ActiveMotif, #39739). Each of these antibodies was validated 
by protein blot or dot blot as described45. Antibody-chromatin complexes were pulled down 
with protein G magnetic beads (Dynabead, 10003D), washed and then eluted. After cross-
link reversal and proteinase K treatment, immunoprecipitated DNA was treated with RNase 
and purified with Agencourt AMPure XP (Beckman Coulter A63880). Libraries were 
prepared according to Illumina’s instructions. ChIP DNA and input controls were sequenced 
with the Illumina HiSeq 2500 or the NextSeq 500 instrument. Reads were aligned to the 
reference genome (hg19) using BWA46. Reads mapping to more than two genomic loci were 
ignored. Reads aligned to the same position and strand were only counted once. All data 
were deposited at the European Genome-phenome Archive (EGA), which is hosted by the 
EBI, under accession number EGAS00001001457.
Statistical analysis
Data for bone marrow derived mesenchymal stem cells and gastric and fetal leg muscle 
tissues are publicly available through the Roadmap Program (GSM1112792, GSM1013128, 
GSM1058767); HMEC, PANC1 and MCF7 cell line data were downloaded from ENCODE 
(GSM733660, GSM818826, GSM945854); data for MGG28 and Ewing sarcoma were 
recently published47,48; MOLT3 data were taken from19.
Peaks and motifs were called using HOMER49. H3K27ac peaks were centered on 
nucleosome free regions, set to be 400bp with a minimal distance of 600bp, and required to 
be 4 fold more than matching input. MYB peaks were called with default parameters. To call 
putative super-enhancers, BRD4 or H3K27ac peaks up to 12.5kb apart were stitched 
together, and enhancers with a slope greater than 1 were considered super enhancers, as 
described in reference15. H3K27ac heat maps were calculated after merging all H3K27ac 
peaks across samples. Signal was normalized by total signal per sample. Only peaks with 
normalized signal > 10 fpm in at least one sample were considered. Inter-sample 
correlations were calculated by Spearman’s rho. Motifs were called with HOMER in a 
300bp region around the peak center. To identify top H3K27ac motifs, known motifs were 
sorted based on median p-value across all samples. To identify differential motifs between 
grades, we merged H3K27ac of all grade 2 and all grade 3 primagrafts, and then defined 
peaks with more than 4 fold higher signal, averaging across 2kb regions in one over the 
other set.
High confidence MYB peaks were called by merging peaks from 3 grade 2 primagrafts, 
summing MYB signal over each peak in each sample, normalizing each sample by the 
average signal of that sample, and selecting peaks where the average signal over all samples 
Drier et al. Page 10
Nat Genet. Author manuscript; available in PMC 2016 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
was at least 0.75. To determine which genes are expressed we used published microarray 
data12, averaging over the 3 samples (log2 space). Any gene with an average expression level 
greater than 5 was considered to be expressed. Peaks were assigned to genes using 
GREAT50, limited to 100kb maximal distance. We calculated GOBP51, MSigDB52 and 
REACTOME53 annotation enrichment of all MYB bound and expressed genes versus all 
expressed genes using Fisher exact test (FDR < 1%). To identify MYB driven transcriptional 
regulators we focused on targets annotated as “positive regulation of transcription, DNA-
templated” by GOBP (GO:0045893) that were found to be significantly enriched (p<3.8 
x10−7) in the analysis above. We then ranked all those genes by total normalized MYB 
signal on all MYB peaks assigned to the respective gene. Normal salivary gland RNA-seq 
data were obtained from the human protein atlas (HPA)20. Genes were divided into “not 
detected”, “low” or “high”, based on HPA definitions, where “high” includes both 
“medium” and “high” genes of HPA definitions. Annotation enrichment of expressed MYB 
targets in a given set was compared to all genes in that set that are expressed in ACC. To test 
expression of MYB targets and non-MYB targets we compared the average expression of the 
expressed MYB targets in ACC as described above to the average expression of other 
expressed (log2 ≥5) genes. To control for MYB independent expression differences between 
those genes we compared the expression of the same sets of genes in normal salivary gland. 
To compare MYB binding profiles to previously published promoters bound by MYB in 
MCF7 cells17, we compared it to the subset of our high confidence MYB peaks above at 
most 2kb from TSS. To compare these MYB binding profiles to previously published MYB 
profiles for mouse myeloid progenitors18, we compared bound genes in mouse (as listed 
there in Supplementary Tables 5 and 6) to homologous human genes (by NCBI’s 
HomoloGene), with assigned high confidence MYB peak in ACC. To estimate BRD4 
overlap with MYB peaks, we called MYB and BRD4 signal on all MYB peaks detected in 
ACCX5M1 and ACCX9, and counted peaks with normalized binding > 30 fpm. To estimate 
TP63 overlap with MYB peaks we called MYB and TP63 signal on all TP63 peaks detected 
in ACCX5M1 and count peaks with normalized binding > 30 fpm.
To quantify MYB signal over enhancers per target gene, MYB peaks more than 2kb away 
from the TSS were assigned to genes using GREAT, limiting maximal distance to 1Mb to 
allow for fair comparison of the wide range of translocated NFIB enhancers. We then 
compared the total MYB signal over the translocated enhancers to the total signal over all 
enhancers of any MYB target.
Significance of 3C analysis was called based on 95% confidence interval not intersecting 
zero interaction. Significance of JQ1 treatment in primagraft experiments was called by one-
tailed student’s t-test at the last time point for which tumor measurements were obtained. 
Significance of qPCR after JQ1 treatment was called by one-tailed student’s t-test between 
JQ1 treated and vehicle.
Quantitative RT-PCR analyses
Frozen tumor tissue was mechanically homogenized and total RNA was extracted with 
Trizol (Life Technologies) followed by the RNeasy Mini Kit (Qiagen) with on-the-column 
DNase treatment. Total RNA was reverse transcribed into cDNA using the SuperScript III 
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First-Strand Synthesis system for RT-PCR. qPCR was performed with FastStart Universal 
SYBR Green Master (Roche) on an ABI 7500 (primer sequences are listed in 
Supplementary Table 6). Gene expression was measured by determining the log2(Ct) value 
of the desired transcript compared to GAPDH transcript. A one-tailed p-value < 0.05 was 
considered statistically significant.
Genomic breakpoint PCR analyses
For validation of genomic rearrangements, genomic DNA was extracted from ACC 
primagrafts using the QiaAmp DNA mini kit (Qiagen). PCR reactions were performed with 
2 min extension times to allow for adequate amplification of longer fragments. PCR 
products were visualized on a 1.5% agarose gel. MYB rearrangements, and representative 
highest confidence and lowest confidence rearrangements were selected for validation (See 
Supplementary Table 1). Rearrangements in 4 primagrafts were validated. The primer 
sequences are listed in Supplementary Table 6.
Reporter assays
Five translocated enhancer sequences and five controls with scrambled MYB consensus 
motifs (replacing CNGTT with GTAAG, see Supplementary Table 6) were synthesized and 
cloned into the pGL 4.23 [luc2/minP] vector (Promega) by BlueHeron. Enhancer activity 
was measured in 6 replicates as relative luminescence of the pGL 4.23 [luc2/minP] vector 
compared to the pGL 4.73 [hRluc/SV40] with Dual-Glo Luciferase (Promega) after a 36 
hour co-nucleofection into Jurkat cells following the manufacturer’s instructions (Amaxa 
cell line nucleofactor kit V from Lonza).
Chromosome Conformation Capture
Chromosome Conformation Capture was performed as described54. In brief, frozen tumor 
tissue was chopped up using a scalpel before fixation and then further dissociated after 
fixation by shearing with an 18G needle. Cross-linked chromatin was then digested with 
500U of HindIII (Roche) overnight at 37°C followed by ligation. 3C products were phenol/
chloroform extracted, ethanol-precipitated, and dissolved in Tris/EDTA buffer. Each PCR 
was performed under the following conditions: 95°C for 10 minutes; 65 cycles at 95°C for 
15 seconds; 60°C for 1 minute; 72°C for 1 minute; and a final extension at 72°C for 10 
minutes. PCR products were analyzed by agarose gel electrophoresis. Primer and TaqMan 
probe sequences are listed in Supplementary Table 6. Any undetected qPCR call, or Ct>50 
were considered as Ct=50. 95% confidence intervals were used to call statistical 
significance.
Immunohistochemistry
Formalin fixed paraffin embedded sections were cut at 4 microns and place on Superfrost 
plus glass slides, which were were baked for 60 minutes at 60° C. Staining was conducted 
on a Leica Bond III automated immunohistochemical staining work station. To stain for 
MYB, antigen retrieval was performed using Bond Epitope Retrieval 1 solution for 30 
minutes. Staining was carried out by incubation with a MYB-specific rabbit monoclonal 
primary antibody (EP769Y, Abcam, ab45150) at 1:400 for 30 minutes at room temperature, 
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followed by incubation with a rabbit-specific secondary antibody linked to horseradish 
peroxidase (Bond Polymer Refine Detection kit). Staining was developed by incubation with 
diaminobenzamidine (Leica Detection Kit), and slides were then dehydrated and 
coverslipped. Dual staining for activated NOTCH1 (ICN1) and p63 was carried out by first 
performing antigen retrieval using Bond Epitope Retrieval 2 solution for 40 minutes. Slides 
were then incubated with ICN1 antibody (D3B8, Cell Signaling Technologies, #4147) at 
1:100 for 60 minutes at room temperature, followed by incubation with a rabbit-specific 
secondary antibody linked to horseradish peroxidase (Bond Polymer Refine Detection kit). 
ICN1 staining was then developed by incubation with diaminobenzamidine (Leica Detection 
Kit). Slides were then incubated in a second primary antibody, a murine monoclonal 
antibody specific for p63 (4A4, Biocare, CM163A) at 1:250 for 30 minutes. The second 
antibody was detected using the murine specific Bond Polymer Refine Red Detection kit, 
which detects staining using Fast Red, part of the detection kit. Slides were then dehydrated 
and coverslipped. Dual staining for ICN1 and KIT was performed as above, using a rabbit 
monoclonal antibody specific for ICN1 (D3B8, Cell Signaling Technologies, #4147) at 
1:100 for 60 minutes at room temperature, and a second primary antibody, a murine 
monoclonal antibody specific for KIT (Dako, A4502), at 1:250 for 30 minutes.
To generate spectral libraries, single-stained tissue sections were imaged using the Mantra 
multispectral imaging platform (PerkinElmer, Hopkinton, MA). The spectrally resolved, 
individual profiles between 420–720 nm of 3,3′-diaminobenzidine (DAB; ICN1), fast red 
(KIT or p63), and the haematoxylin counterstain were used to deconvolute staining patterns 
in triple-stained tissue sections. Three representative areas of each stained tissue section 
were imaged at 20x magnification and deconvoluted using the Inform 2.1 software package 
(PerkinElmer). Each image was manually divided into tumor and stromal tissue, and 
individual tumor cells were segmented using Inform 2.1 algorithms that score positive 
staining of nuclei and cell membranes for each color.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. MYB translocations involve alternate partners and frequently retain the 3′ UTR
a. Circos plots of inter-chromosomal translocations in 6 ACC primagrafts. Only MYB 
translocations (marked in purple) occur in more than 2 tumors. b. For a cohort of 20 tumors, 
pie chart depicts fraction of MYB translocations that involve the NFIB locus, with or 
without loss of the MYB 3′UTR, or that rearrange to other loci (TGFBR3 or RAD51B). 
These rearrangements to alternative partners retain the MYB 3′UTR. c. Log plot shows 
MYB mRNA expression in ACC primagrafts, relative to normal salivary gland. Error bars 
reflect standard error of means (SEM, n=3 experiments per sample); p < 10−5 compared to 
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normal in all cases. These data suggest that neither UTR loss nor NFIB fusion is sufficient to 
explain robust MYB overexpression in ACC.
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Figure 2. Translocation partners contain super-enhancers that loop to the MYB promoter
a. H3K27ac (enhancer) profiles are shown for alternate ACC rearrangements: MYB-NFIB 
translocation with loss of MYB 3′UTR (X16); MYB-NFIB translocation with retained 
3′UTR (X19); and MYB-TGFBR3 translocation with retained MYB 3′UTR (X6). Arrows 
indicate the rearrangements. H3K27ac signal is scaled in fragments per million. b. 
Candidate enhancers ranked by H3K27ac signal in ACC primagrafts diagramed in Panel a. 
Expansive enhancers in the NFIB (red and purple) and TGFBR3 (blue) loci satisfy super-
enhancer criteria. These enhancers score similarly in other tumors (Supplementary Fig. 3). c. 
H3K27ac (enhancer) profiles for the NFIB locus (negative strand shown) in 5ACCs and 6 
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MYB-NFIB positive primagrafts. Enhancers are numbered as indicated (En1–En8). 
Translocations occur close to the 5′UTR of NFIB near the En1 enhancer (black triangles). 
Bars below peaks mark super-enhancers. d. Chromosome Conformation Capture (3C) 
demonstrates looping of translocated enhancers to MYB promoter in X19. The plot depicts, 
for each enhancer (En1–En8) or control site, its normalized interaction frequency with the 
MYB promoter. Significant interactions (p<0.05) are marked by ‘*’, and error bars show 
SEM (n=5). e. H3K27ac profiles for the TGFBR3 locus (negative strand) in 5 ACCs and 2 
MYB-TGFBR3 positive primagrafts. Translocations occur within TGFBR3, near the Et1 
enhancer (black triangles). f. 3C demonstrates looping of translocated enhancers to MYB 
promoter in X6 (MYB-TGFBR3 rearrangement), as in Panel d. Error bars show SEM (n=5). 
These data suggest that alternate ACC rearrangements juxtapose super-enhancers to the 
MYB locus that physically interact with the MYB promoter, and activate its expression.
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Figure 3. MYB protein binds translocated super-enhancers and other active enhancers
a. MYB binding and H3K27ac profiles are shown for the NFIB locus in X16 or the 
TGFBR3 locus in X2 (negative strand shown). MYB-bound enhancers looping to MYB 
promoter are labeled as in Figure 2c–f. b. Box plot depicts distribution of MYB signal over 
enhancers in ACCs. Box shows quartiles (q1, q2, q3), whiskers extending to q3+1.5*(q3 q1). 
Super-enhancers in the NFIB locus are top-ranked MYB targets in tumors with MYB-NFIB 
translocation (red points; #5 in X5M1, #17 in X16). Super-enhancers in the TGFBR3 locus 
are top-ranked MYB targets in tumors with MYB-TGFBR3 (#77 in X2). c. Schematic 
depicts positive feedback loop, engaged by chromosomal rearrangements, that sustains 
MYB overexpression in ACC. d. High confidence MYB peaks in three grade 2 primagrafts 
(see methods) were annotated as ‘promoter’ (+/− 2kb from TSS; top) or ‘enhancer’ 
(bottom). Heat maps show MYB and H3K4me3 signals over 2776 promoters (rows; 5Kb 
regions centered on MYB peaks, ranked by MYB signal), or MYB and H3K27ac signals 
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over 10502 enhancers (rows; 5Kb regions centered on MYB peaks, ranked by MYB signal). 
e. Expression of MYB target genes, compared to control genes, in ACC primagrafts (left) 
and normal salivary gland (right). High expression of genes near MYB binding sites 
supports a role for MYB as a transcriptional activator in ACC. f. MYB target genes ranked 
by cumulative MYB signal over promoter and nearby enhancers (Notch pathway genes in 
red). g. Heat map shows enhancers with preferential H3K27 acetylation in grade 2 (top) or 
grade 3 (bottom) primagrafts. TF motifs enriched in the respective enhancer groups are 
indicated.
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Figure 4. MYB drives alternate cell fates in ACC
a. Images show H&E stains and immunohistochemistry for Ki-67, KIT, TP63 and activated 
NOTCH1 (ICN1) in two grade 2 and two grade 3 primagrafts. Scale bar is 100μm. Grade 2 
tumors have a cribriform histology with a mixture of myoepithelial (TP63) and luminal 
epithelial cells (KIT, ICN1). Grade 3 tumors show strong Notch activation with loss of 
myoepithelial cells (TP63). b. Co-staining of ICN1 and TP63 or ICN1 and KIT in a grade 2 
ACC (top 2 panels) and grade 3 ACC (bottom 2 panels). Scale bar is 100μm. Expression of 
ICN1 and TP63 are almost always mutually exclusive.
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Figure 5. BET inhibition slows tumor growth in grade 2 ACC primagrafts
a. Experimental design for ACC xenotransplantation trials with the BET bromodomain 
inhibitor JQ1. ACC cells from four different human tumors were transplanted into the flanks 
of nude mice. Once tumor size reached 200 – 300 cc, mice were randomized into 2 
treatment groups (vehicle or JQ1). Mice were treated daily, and were monitored for disease 
burden. The trial was stopped when mice became moribund. b. Average tumor size from 3–9 
mice per group is depicted during the period of the xenotransplantation trial (Grade 2 
tumors: X6, X5M1; grade 3 tumors: X9, X11). Error bars show standard error of means. c. 
Plot shows mRNA expression of MYB and selected MYB target genes after JQ1 treatment 
(normalized to GAPDH; * = p<10−2, ** = p<10−3, *** = p<10−4, **** = p<10−5; error bars 
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show standard error of means, n=3). BET inhibition slows growth and leads to 
downregulation of MYB and MYB target genes in grade 2 tumors.
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